FDA clears IND application for CD19/CD20 dual-targeting in vivo CAR-T therapy LB2501
LB2501 is the first known dual-targeting in vivo CAR-T therapy to receive FDA IND clearance. Built on the proprietary TaVec platform, the off-the-shelf,
Cellular Therapy
Lymphoma
Aggressive B-Cell Lymphomas
Indolent B-Cell Lymphomas
Mantle Cell Lymphoma
News
Community Oncology News
Community Oncology
Marin Xavier, MD, presents on ‘Integrating new evidence into everyday practice’
Host Dr. Loretta Nastoupil also discusses with Dr. Xavier how to navigate second-line regimens like monoclonal antibodies versus bispecific T-cell engagers and manage
FOCUS on DREAMM
Multiple Myeloma
News
Video Interviews
Experts offer advice on treating patients with belantamab mafodotin-based combinations in myeloma
Offering practical advice for community physicians on managing toxicities while maintaining efficacy, Dr. Nooka explained how to modify standard schedules.
Leukemia
Chronic Lymphocytic Leukemia
FDA approves pirtobrutinib for untreated chronic lymphocytic leukemia and small lymphocytic lymphoma
"This approval is grounded in data from BRUIN CLL-313, which showed a significant delay in disease progression for pirtobrutinib compared to chemoimmunotherapy, along
MPN News
SOHO 2026
Meetings / Conferences
Myeloproliferative Neoplasms
Video Interviews
SENTRY trial shows early survival benefit with selinexor plus ruxolitinib in myelofibrosis
The discussion highlights key findings, including a significant improvement in spleen volume response for the selinexor-plus-ruxolitinib combination arm alongside similar symptom relief across
FOCUS on DREAMM
Roundtable Discussions
Video Interviews
How do the DREAMM-7 and DREAMM-8 trials compare?
“...these are ... complementary regimens that could be given to suitable patients,” Dr. Dimopoulos said, explaining how DREAMM-7 fits patients progressing on lenalidomide
Trending now
Leukemia
Chronic Lymphocytic Leukemia
Lymphoma
Indolent B-Cell Lymphomas
News
China NMPA approves pirtobrutinib in CLL/SLL across all lines of therapy
Building upon its previous approval in the relapsed or refractory setting, this expanded indication is based on data from the global phase 3
FOCUS on DREAMM
Trending now
Roundtable Discussions
Video Interviews
‘Where is the threshold?’ DREAMM-9 belamaf dosing
“… where is the threshold where you can get really good MRD negativity, good responses in this older patient population without causing ocular
Acute Myeloid Leukemia
MDS News
SOHO 2026
Meetings / Conferences
News
Society Updates
Young Investigator Program
Meet some of the SOHO 2026 Young Investigators
The Society of Hematologic Oncology is proud to highlight some of the exceptional clinicians and researchers participating in the SOHO 2026 Young Investigator
SOHO 2026
Meetings / Conferences
Video Interviews
Society Updates
Save the date: SOHO 2027 scheduled for August 25–28
SOHO 2027 is scheduled for August 25–28, 2027, in Houston, Texas at the George R. Brown Convention Center.